List of Dsuvia drug patents
Dsuvia is owned by Acelrx Pharms.
Dsuvia contains Sufentanil Citrate.
Dsuvia has a total of 18 drug patents out of which 0 drug patents have expired.
Dsuvia was authorised for market use on 02 November, 2018.
Dsuvia is available in tablet;sublingual dosage forms.
Dsuvia can be used as treatment of acute pain.
The generics of Dsuvia are possible to be released after 29 July, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778393 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US9320710 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US10342762 | ACELRX PHARMS | Small-volume oral transmucosal dosage forms |
Jan, 2027
(3 years from now) | |
| US8231900 | ACELRX PHARMS | Small-volume oral transmucosal dosage |
Jan, 2027
(3 years from now) | |
| US8252328 | ACELRX PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(3 years from now) | |
| US9744129 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8252329 | ACELRX PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(3 years from now) | |
| US8226978 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8865211 | ACELRX PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(3 years from now) | |
| US10245228 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US10507180 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8535714 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8778394 | ACELRX PHARMS | Small-volume oral transmucosal dosage forms |
Jan, 2027
(3 years from now) | |
| US8574189 | ACELRX PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(7 years from now) | |
| US10896751 | ACELRX PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(7 years from now) | |
| US8202535 | ACELRX PHARMS | Small-volume oral transmucosal dosage forms |
Oct, 2030
(7 years from now) | |
| US8865743 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Oct, 2030
(7 years from now) | |
| US8945592 | ACELRX PHARMS | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
Jul, 2031
(8 years from now) | |
Drugs and Companies using SUFENTANIL CITRATE ingredient
Market Authorisation Date: 02 November, 2018
Treatment: Treatment of acute pain
Dosage: TABLET;SUBLINGUAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic